Navigating Market Trends, Personal Finance Tips, and Economic Insights

Will Defensive Sectors Outperform Growth in 2024?

Key Points

  • Healthcare stocks took the lead in the first week of 2024, with notable performers including Moderna, Merck, and Viatris.
  • Other traditional defensive sectors, such as energy, consumer staples and utilities, also saw positive momentum.
  • In uncertain economic conditions, investors often turn to the lower volatility and reliable income that are hallmarks of defensive stocks.
  • 5 stocks we like better than Altria Group

Defensive sectors are off to a better start to the new year than growth stocks, which dominated in 2023. 

The Health Care Select Sector SPDR Fund NYSEARCA: XLV, which has both growth and defensive characteristics, was the leader in the first week of the year. Top sector performers included Moderna Inc. NASDAQ: MRNA, Merck & Co., Inc. NYSE: MRK and Viatris Inc. NASDAQ: VTRS.

Energy stocks, consumer staples and utilities stocks, all traditional defensives, rounded out the list of those starting the year with gains.  

In the Energy Select Sector SPDR Fund NYSEARCA: XLE, top performers at the beginning of the year were Marathon Petroleum Corp. NYSE: MPC, The Williams Companies, Inc., NYSE: WMB and Exxon Mobil Corp. NYSE: XOM.

Utilities Select Sector SPDR Fund NYSEARCA: XLU leaders were Pinnacle West Capital Corp. NYSE: PNW, FirstEnergy Corp. NYSE: FE and Xcel Energy Inc. NASDAQ: XEL.

Within the Consumer Staples Select Sector SPDR Fund NYSEARCA: XLP, The Hershey Co. NYSE: HSY, Altria Group Inc. NYSE: MO and Sysco Corp. NYSE: SYY led the pack. 

Defensives rotating into leadership?

In years following the dominance of growth stocks, as we saw in 2023, it’s not uncommon for defensives to rotate into leadership.

This shift can occur as investors reassess their risk tolerance and seek stability amid economic uncertainties, plenty of which remain in 2024, despite inflation easing and the job market remaining robust. 

Defensive sectors, including utilities and consumer staples, become more appealing due to their lower volatility, as well as reliability when it comes to dividends.

In years when defensive stocks take the lead, the S&P 500 tends to reflect a preference for stability and income amid economic uncertainties. These years are marked by characteristics such as:

  • Lower Overall Returns: Defensive stocks are known for their reliability in uncertain economic conditions, yet they contribute comparatively lower overall returns for the S&P 500. 
  • Interest Rate Sensitivity: Defensive stocks are particularly sensitive to interest rate movements, although that’s true of some growth sectors as well, such as the Technology Select Sector SPDR Fund NYSEARCA: XLK. If rates are cut in 2024, as expected, dividend-paying defensive stocks may become more attractive.
  • Market Rotation: A leadership role by defensive stocks often signifies a rotation away from high-beta sectors like tech, communications or consumer discretionary. This shift happens as investors favor assets perceived as more stable during challenging economic environments.

So what are defensive stocks exactly? They’re definitely not as glamorous as techs, and don’t show the kind of sky-high rallies of a stock like Nvidia Corp. NASDAQ: NVDA, which returned 240% in 2023. 

Defensives can rally even as AI innovation continues

As an additional draw, many defensive stocks offer regular dividend payments, providing investors with a consistent income stream. The reliability of sales regardless of an economic cycle contributes to these companies’ ability to continue returning capital to shareholders through dividends. 

Checkup on healthcare stocks

While Moderna, Merck and Viatris are the best performers among healthcare stocks, they’re also the S&P 500 leaders in the first week of January. 

There are reasons to be cautious, as well as optimistic about healthcare stocks in 2024. 

On the cautionary side, healthcare stocks often underperform in presidential election years, as investors become concerned about possible regulatory changes that could put a dent in earnings. Already, Medicare drug price negotiations are on the horizon, which could affect companies including Merck, , and .

Before you consider Altria Group, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Altria Group wasn’t on the list.

While Altria Group currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Share this article
Shareable URL
Prev Post

How Verizon Customers Can Claim a Share of the $100 Million Settlement

Next Post

Assessment of Japanese Firm’s Offer for U.S. Steel Challenges Biden’s Manufacturing Strategy

Leave a Reply

Your email address will not be published. Required fields are marked *

Read next
Looking to score big with casino stocks? The house may have the edge when you sit at the table, but investors…
Key Points As two oil giants fight over who will win Hess’s takeover bid, investors can find a way to play…
Outlook Therapeutics NASDAQ: OTLK has gained attention, with analysts forecasting an upside of over 500% based…
Key Points Salesforce was trading at an all-time high just a few months ago, and analysts expect it to get back…